Lipid Metabolism Practice Questions

Q: Which of the following lipids is associated with respiratory distress syndrome?

Dipalmitoyl lecithin. ### Explanation **Correct Option: C. Dipalmitoyl lecithin** **Mechanism and Clinical Correlation:** Respiratory Distress Syndrome (RDS), specifically Neonatal RDS (Hyaline Membrane Disease), is caused by a deficiency of **pulmonary surfactant**. Surfactant is a lipoprotein complex synthesized by **Type II pneumocytes**. Its primary function is to reduce surface tension at the alveolar air-liquid interface, preventing alveolar collapse (atelectasis) during expiration. The major lipid component of surfactant (comprising about 80%) is phospholipids, and the most abundant and active constituent is **Dipalmitoylphosphatidylcholine (DPPC)**, also known as **Dipalmitoyl lecithin**. It acts as a detergent; its amphipathic nature allows it to spread across the alveoli, lowering the pressure required to keep them inflated. **Analysis of Incorrect Options:** * **A. Phosphatidylethanolamine (Cephalin):** Found primarily in nervous tissue and cell membranes; it is not a major component of lung surfactant. * **B. Phosphatidylserine:** Important for cell signaling and apoptosis (it flips to the outer leaflet to signal "eat me" to macrophages), but plays no role in surface tension reduction. * **D. Phosphatidylinositol:** A precursor for second messengers like $IP_3$ and $DAG$; while present in small amounts in surfactant, it is not the primary functional lipid associated with RDS. **High-Yield NEET-PG Pearls:** * **L/S Ratio:** Fetal lung maturity is assessed via the **Lecithin/Sphingomyelin ratio** in amniotic fluid. A ratio **> 2.0** indicates mature lungs. * **Glucocorticoids:** Given to mothers in preterm labor (e.g., Betamethasone) to stimulate surfactant production by inducing fibroblast pneumocyte factor. * **Surfactant Proteins:** SP-A and SP-D are involved in innate immunity, while **SP-B and SP-C** are crucial for the mechanical spreading of the surfactant film. Deficiency of SP-B is a rare genetic cause of RDS.

Q: Ketone bodies are synthesized in which part of the body?

Liver. **Explanation:** **1. Why the Liver is Correct:** Ketone bodies (Acetoacetate, 3-hydroxybutyrate, and Acetone) are synthesized primarily in the **mitochondria of liver hepatocytes**. This process, known as ketogenesis, occurs when there is an excess of Acetyl-CoA (derived from fatty acid β-oxidation) that cannot enter the TCA cycle due to a depletion of oxaloacetate (e.g., during starvation or uncontrolled diabetes). The rate-limiting enzyme for this process is **HMG-CoA synthase**, which is highly expressed in the liver. **2. Why Other Options are Incorrect:** * **Brain & Heart (Options A & C):** These organs are major **consumers** of ketone bodies, not producers. While the brain normally relies on glucose, it adapts to use ketones during prolonged fasting. The heart prefers fatty acids but can readily oxidize ketones. They lack the enzymatic machinery for synthesis. * **Intestine (Option D):** While the intestinal mucosa can produce small amounts of ketones during development or specific dietary states, it is not a primary site of synthesis and is clinically insignificant compared to the liver. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Liver Paradox":** Although the liver synthesizes ketone bodies, it **cannot utilize them** because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Ketone Body Ratio:** The ratio of 3-hydroxybutyrate to acetoacetate depends on the NADH/NAD+ ratio in the mitochondria. * **Detection:** The **Rothera’s Test** detects Acetoacetate and Acetone, but **not** 3-hydroxybutyrate. * **Key Enzyme:** HMG-CoA **Synthase** is for Ketogenesis; HMG-CoA **Reductase** is for Cholesterol synthesis.

Q: Triacylglycerol synthesis is enhanced by which of the following hormones?

Insulin. **Explanation:** **1. Why Insulin is Correct:** Insulin is the primary anabolic hormone of the body, promoting energy storage. In the "well-fed state," insulin enhances **Triacylglycerol (TAG) synthesis** (Lipogenesis) through several mechanisms: * **Glucose Uptake:** It increases glucose entry into adipocytes via GLUT-4, providing **Glycerol-3-phosphate** (the backbone for TAG). * **Enzyme Activation:** It activates **Acetyl-CoA Carboxylase**, the rate-limiting enzyme for fatty acid synthesis. * **Lipoprotein Lipase (LPL) Induction:** Insulin stimulates LPL in the capillary walls of adipose tissue, allowing the uptake of free fatty acids from chylomicrons and VLDL for storage. * **Inhibition of Lipolysis:** It inhibits Hormone-Sensitive Lipase (HSL), preventing the breakdown of stored fats. **2. Why Other Options are Incorrect:** * **Glucagon & Epinephrine:** These are catabolic hormones. They stimulate **Lipolysis** (breakdown of TAGs) by activating Hormone-Sensitive Lipase via the cAMP pathway to provide fuel during fasting or stress. They inhibit TAG synthesis. * **Co-isoleucine:** This is not a recognized hormone involved in lipid regulation; isoleucine is a branched-chain amino acid. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme of Lipogenesis:** Acetyl-CoA Carboxylase (requires Biotin). * **Rate-limiting enzyme of Lipolysis:** Hormone-Sensitive Lipase (HSL). * **The "Insulin-Glucagon Ratio":** A high ratio favors lipogenesis (storage), while a low ratio (fasting/diabetes) favors ketogenesis and lipolysis. * **Glycerol Kinase:** Adipose tissue lacks this enzyme; therefore, it must rely on glucose metabolism (DHAP) to produce Glycerol-3-phosphate for TAG synthesis. This makes fat storage dependent on insulin-mediated glucose uptake.

Q: Infant with carnitine deficiency forms hypoglycemia due to what reason?

Reduced fatty acid oxidation and ketogenesis. **Explanation:** The primary defect in carnitine deficiency is the inability to transport long-chain fatty acids (LCFAs) across the inner mitochondrial membrane. Carnitine is essential for the **"Carnitine Shuttle"** (involving CPT-I and CPT-II). Without it, **β-oxidation of fatty acids** cannot occur. **Why Option D is correct:** In a fasting state, the body relies on fatty acid oxidation to provide the energy (ATP) and reducing equivalents (NADH) required for gluconeogenesis. Furthermore, β-oxidation produces **Acetyl-CoA**, which is an obligatory allosteric activator of **Pyruvate Carboxylase** (the rate-limiting enzyme of gluconeogenesis). Reduced β-oxidation leads to: 1. **Hypoglycemia:** Due to insufficient energy and lack of Acetyl-CoA to drive gluconeogenesis. 2. **Hypoketosis:** Since Acetyl-CoA is the precursor for ketone bodies, its absence prevents ketogenesis. This results in the classic presentation of **hypoketotic hypoglycemia**. **Why other options are incorrect:** * **A & C:** In carnitine deficiency, the body actually *increases* glucose utilization and glycolysis to compensate for the lack of fatty acid energy, which further exacerbates the hypoglycemia. * **B:** While gluconeogenesis is indeed decreased, it is a *consequence* of reduced fatty acid oxidation (Option D), which is the primary biochemical mechanism. **NEET-PG High-Yield Pearls:** * **Clinical Triad:** Hypoketotic hypoglycemia, hyperammonemia (due to urea cycle dysfunction from low ATP), and cardiomyopathy/skeletal muscle weakness. * **CPT-I vs. CPT-II:** CPT-I is located in the outer mitochondrial membrane and is inhibited by **Malonyl-CoA** (the first committed intermediate of fatty acid synthesis). * **Treatment:** Avoid prolonged fasting; provide a diet high in carbohydrates and medium-chain triglycerides (MCTs), as MCTs do not require the carnitine shuttle to enter the mitochondria.

Q: What is the effect of estrogen in pre-menopausal women on the lipid profile?

Increased high-density lipoproteins. **Explanation:** Estrogen plays a pivotal role in lipid metabolism, which explains why pre-menopausal women generally have a lower risk of cardiovascular disease compared to men and post-menopausal women. **Why the correct answer is right:** Estrogen exerts a cardioprotective effect primarily by **increasing High-Density Lipoprotein (HDL)** levels. It achieves this by stimulating the synthesis of Apolipoprotein A-I (the primary protein in HDL) and inhibiting the activity of **Hepatic Lipase**, the enzyme responsible for HDL degradation. Additionally, estrogen enhances the expression of LDL receptors in the liver, leading to **decreased Low-Density Lipoprotein (LDL)** levels. **Analysis of Incorrect Options:** * **A. Decreased HDL:** Incorrect. Estrogen increases HDL by reducing its clearance. * **B. Increased LDL:** Incorrect. Estrogen actually lowers LDL levels by increasing the clearance of LDL particles from the circulation via up-regulation of hepatic LDL receptors. * **D. Increased total cholesterol:** Incorrect. While estrogen can slightly increase VLDL (triglycerides), the overall effect is a reduction in total cholesterol due to the significant drop in LDL. **NEET-PG High-Yield Pearls:** * **Post-menopausal shift:** After menopause, the drop in estrogen leads to an increase in LDL and a decrease in HDL, significantly increasing the risk of Atherosclerotic Cardiovascular Disease (ASCVD). * **Triglyceride Paradox:** Oral estrogen therapy can actually **increase serum triglycerides** by stimulating VLDL synthesis in the liver. * **Enzyme Inhibition:** Remember that estrogen inhibits **Hepatic Lipase**; this is a common "fact-check" point in biochemistry exams.

Q: All the following are associated with increased risk of coronary heart disease except?

Familial hyperalphalipoproteinemia. **Explanation:** The core concept tested here is the distinction between pro-atherogenic and anti-atherogenic lipoproteins. **Why Option C is Correct:** **Familial Hyperalphalipoproteinemia** is a rare genetic condition characterized by abnormally high levels of **High-Density Lipoprotein (HDL)**, often due to a deficiency in Cholesteryl Ester Transfer Protein (CETP). Since HDL is responsible for "Reverse Cholesterol Transport"—shuttling cholesterol from peripheral tissues back to the liver—it is highly cardioprotective. Therefore, this condition is associated with a **decreased** risk of coronary heart disease (CHD) and increased longevity. **Why the other options are incorrect:** * **A. Familial Hypercholesterolemia:** Caused by a defect in LDL receptors, leading to extremely high levels of LDL ("bad cholesterol"). This is a major risk factor for premature atherosclerosis and myocardial infarction. * **B. Familial Hyperacylglycerolemia (Hypertriglyceridemia):** Elevated VLDL and triglycerides are independent risk factors for CHD and are often associated with metabolic syndrome and low HDL. * **C. Hepatic Lipase Deficiency:** This enzyme is crucial for converting IDL to LDL and converting HDL2 to HDL3. Its deficiency leads to the accumulation of cholesterol-rich VLDL remnants and IDL (Beta-VLDL), which are highly atherogenic. **High-Yield Clinical Pearls for NEET-PG:** * **HDL (The "Good" Lipoprotein):** Contains **Apo A-I**. It is anti-atherogenic, anti-inflammatory, and anti-oxidant. * **LDL (The "Bad" Lipoprotein):** Contains **Apo B-100**. It is the primary carrier of cholesterol to peripheral tissues. * **CETP Inhibitors:** Drugs like Anacetrapib aim to mimic familial hyperalphalipoproteinemia to raise HDL levels, though their clinical utility in reducing CV events remains a subject of research. * **Friedewald Formula:** LDL = Total Cholesterol – (HDL + TG/5). (Note: Not applicable if TG >400 mg/dL).

Q: What is the major storage form of fatty acids in the body?

Triacylglycerols. **Explanation:** **Triacylglycerols (TAGs)**, also known as triglycerides, are the primary storage form of fatty acids in the human body. They consist of three fatty acid chains esterified to a single glycerol backbone. TAGs are stored predominantly in **adipose tissue** within specialized cells called adipocytes. **Why Triacylglycerols are the ideal storage form:** 1. **Energy Density:** They are highly reduced molecules, yielding approximately 9 kcal/g (compared to 4 kcal/g for carbohydrates). 2. **Hydrophobicity:** Unlike glycogen, TAGs are anhydrous (stored without water), allowing for a massive amount of energy to be packed into a small volume without increasing the cell's osmotic pressure. **Analysis of Incorrect Options:** * **B. Cholesteryl esters:** These are the storage form of cholesterol within cells and are found in the core of lipoproteins (like LDL), but they are not the primary storage form for fatty acids. * **C. Cholesterol:** This is a structural component of cell membranes and a precursor for steroid hormones and bile acids; it is not used as an energy storage fuel. * **D. Ketones:** These (acetoacetate, β-hydroxybutyrate) are water-soluble energy alternatives produced by the liver during starvation or prolonged exercise, but they are transport forms, not storage forms. **High-Yield Clinical Pearls for NEET-PG:** * **Hormone-Sensitive Lipase (HSL):** This is the rate-limiting enzyme for mobilizing fatty acids from adipose tissue (stimulated by Glucagon/Epinephrine). * **Brown Adipose Tissue:** Contains **Thermogenin (UCP-1)**, which uncouples the electron transport chain to generate heat instead of ATP. * **Steatosis:** Excessive accumulation of TAGs in non-adipose tissues (like the liver) leads to fatty liver disease.

Q: Fatty acid synthesis and degradation are similar in that both processes:

Use acyl CoA-thioesters. **Explanation:** The correct answer is **B. Use acyl CoA-thioesters**. Both fatty acid synthesis (lipogenesis) and degradation (beta-oxidation) involve the formation of high-energy thioester bonds between the fatty acid chain and a carrier molecule. In degradation, the intermediates are linked to **Coenzyme A (CoA)**. In synthesis, while the intermediates are primarily bound to the **Acyl Carrier Protein (ACP)**, the initial priming steps and the final release involve CoA-thioesters. **Why other options are incorrect:** * **A. Take place in the mitochondrion:** Fatty acid **degradation** occurs in the mitochondria, but **synthesis** occurs primarily in the **cytosol**. (Note: Elongation can occur in the ER/mitochondria). * **C. Use NADPH or NADP as a cofactor:** Synthesis uses **NADPH** (as a reducing agent), whereas degradation uses **NAD+ and FAD** (as oxidizing agents). * **D. Have malonyl CoA as an intermediate:** Malonyl CoA is a key intermediate and regulator of **synthesis**; it does not exist as an intermediate in the degradation pathway. In fact, Malonyl CoA inhibits *Carnitine Palmitoyltransferase I (CPT-1)* to prevent simultaneous synthesis and breakdown. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzymes:** Acetyl CoA Carboxylase (Synthesis) vs. CPT-1 (Degradation/Transport). * **The "Citrate Shuttle":** Citrate carries acetyl groups from the mitochondria to the cytosol for synthesis. * **The "Carnitine Shuttle":** Carnitine transports long-chain fatty acids into the mitochondria for degradation. * **Energy Source:** NADPH for synthesis is mainly supplied by the **HMP Shunt** (Pentose Phosphate Pathway).

Q: All are required for the formation of estradiol except?

11b-hydroxylase. The synthesis of **Estradiol** (the primary female sex hormone) follows the steroidogenic pathway starting from Cholesterol. To answer this question, one must distinguish between the synthesis of **Sex Steroids** and **Adrenal Corticosteroids**. ### Why 11β-hydroxylase is the Correct Answer **11β-hydroxylase** is an enzyme exclusively involved in the **Glucocorticoid and Mineralocorticoid pathways**. It converts 11-deoxycortisol to Cortisol and 11-deoxycorticosterone to Corticosterone. It is located in the Zona Fasciculata and Zona Glomerulosa of the adrenal cortex. It plays **no role** in the synthesis of androgens or estrogens. ### Explanation of Incorrect Options * **Lyase (17,20-lyase):** This enzyme is crucial for converting 17-hydroxypregnenolone/progesterone into androgens (DHEA and Androstenedione), which are the direct precursors to estrogens. * **Aromatase (CYP19A1):** This is the **rate-limiting enzyme** for estrogen synthesis. It converts androgens (testosterone and androstenedione) into estrogens (estradiol and estrone) by "aromatizing" the A-ring. * **Hydroxysteroid dehydrogenase (3β-HSD & 17β-HSD):** These enzymes are essential for converting inactive precursors into active hormones. Specifically, **17β-HSD** converts Androstenedione to Testosterone and Estrone to Estradiol. ### High-Yield NEET-PG Pearls * **Two-Cell, Two-Gonadotropin Theory:** LH stimulates **Theca cells** to produce androgens (using Lyase), while FSH stimulates **Granulosa cells** to convert those androgens to estradiol (using Aromatase). * **Congenital Adrenal Hyperplasia (CAH):** A deficiency in **11β-hydroxylase** leads to decreased cortisol but **increased androgens** (virilization), as precursors are shunted away from the corticosteroid pathway toward the sex steroid pathway. * **Aromatase Inhibitors** (e.g., Letrozole, Anastrozole) are clinically used in the treatment of ER-positive breast cancer.

Q: Where is HDL synthesized and secreted from?

Liver. **Explanation:** High-Density Lipoprotein (HDL) is primarily synthesized and secreted by the **Liver** and, to a lesser extent, the **Small Intestine**. It is initially secreted as "nascent HDL," which are discoidal particles composed mainly of phospholipids (lecithin) and apolipoproteins (Apo A-I, A-II, C, and E). **Why the other options are incorrect:** * **Peripheral Tissues:** These tissues do not synthesize HDL. Instead, they are the *source* of excess cholesterol. HDL acts as a scavenger, picking up cholesterol from peripheral tissues via the ABCA1 transporter to transport it back to the liver (Reverse Cholesterol Transport). * **Adipose Tissue:** This is the primary site for triglyceride storage, not lipoprotein synthesis. It interacts with VLDL and Chylomicrons via Lipoprotein Lipase (LPL) but does not produce HDL. * **Muscle:** Similar to adipose tissue, muscle is a site for fatty acid oxidation and utilizes lipids delivered by other lipoproteins but lacks the enzymatic machinery to synthesize HDL particles. **High-Yield NEET-PG Pearls:** 1. **Reverse Cholesterol Transport:** This is the most important function of HDL, making it "Good Cholesterol" because it protects against atherosclerosis. 2. **Apo A-I:** This is the major apolipoprotein associated with HDL and serves as an activator for the enzyme **LCAT** (Lecithin-Cholesterol Acyltransferase). 3. **LCAT Function:** It converts free cholesterol into cholesterol esters within the HDL particle, transforming discoidal nascent HDL into spherical mature HDL (HDL3 and HDL2). 4. **CETP (Cholesterol Ester Transfer Protein):** Facilitates the exchange of cholesterol esters from HDL for triglycerides from VLDL/LDL.

Question 1

Which of the following lipids is associated with respiratory distress syndrome?

Accepted Answer

Dipalmitoyl lecithin

Answer

Phosphatidylethanolamine (cephalin)

Answer

Phosphatidylserine

Answer

Phosphatidylinositol

Question 2

Ketone bodies are synthesized in which part of the body?

Accepted Answer

Liver

Answer

Brain

Answer

Heart

Answer

Intestine

Question 3

Triacylglycerol synthesis is enhanced by which of the following hormones?

Accepted Answer

Insulin

Answer

Co-isoleucine

Answer

Glucagon

Answer

Epinephrine

Question 4

Infant with carnitine deficiency forms hypoglycemia due to what reason?

Accepted Answer

Reduced fatty acid oxidation and ketogenesis

Answer

Decreased glycolysis

Answer

Decreased gluconeogenesis

Answer

Increased utilization of glucose

Question 5

What is the effect of estrogen in pre-menopausal women on the lipid profile?

Accepted Answer

Increased high-density lipoproteins

Answer

Decreased high-density lipoproteins

Answer

Increased low-density lipoproteins

Answer

Increased total cholesterol

Question 6

All the following are associated with increased risk of coronary heart disease except?

Accepted Answer

Familial hyperalphalipoproteinemia

Answer

Familial hypercholesterolemia

Answer

Familial hyperacylglycerolemia

Answer

Hepatic lipase deficiency

Question 7

What is the major storage form of fatty acids in the body?

Accepted Answer

Triacylglycerols

Answer

Cholesteryl esters

Answer

Cholesterol

Answer

Ketones

Question 8

Fatty acid synthesis and degradation are similar in that both processes:

Accepted Answer

Use acyl CoA-thioesters

Answer

Take place in the mitochondrion

Answer

Use NADPH or NADP as a cofactor

Answer

Have malonyl CoA as an intermediate

Question 9

All are required for the formation of estradiol except?

Accepted Answer

11b-hydroxylase

Answer

Lyase

Answer

Aromatase

Answer

Hydroxysteroid dehydrogenase

Question 10

Where is HDL synthesized and secreted from?

Accepted Answer

Liver

Answer

Peripheral tissue

Answer

Adipose tissue

Answer

Muscle

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?